ReviewImmunity, inflammation and disease2026
Human Leukocyte Antigen (HLA) and Tumor Immunity: A Critical Link in Cancer Immunotherapy.
Review in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human Leukocyte Antigen (HLA) and Tumor Immunity: A Critical Link in Cancer Immunotherapy.Immunity, inflammation and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant tumors pose a serious threat to human health and survival, with profound economic consequences worldwide. Human leukocyte antigens (HLAs), encoded by the human major histocompatibility complex, represent one of the most polymorphic genetic systems and play a vital role in immune regulation. This review summarizes the structural and functional characteristics of HLA molecules, their polymorphism and expression in tumor tissues, their involvement in tumor progression and immune responses, and their emerging applications in tumor immunotherapy.
methodsA thorough literature review was conducted focusing on HLA molecules, their genetic variability in tumor tissues, and their impact on tumor immunity and cellular proliferation. The potential clinical utility of targeting HLA molecules in tumor immunotherapy was also evaluated.
resultsHLA polymorphisms and expression patterns have been closely associated with tumor initiation, progression, and immune modulation. These molecules influence tumor cell growth and regulate antitumor immune responses, either enhancing or suppressing immunity. HLA molecules are therefore critical in shaping the immune system's capacity to detect and eliminate cancer cells.
conclusionThis review underscores the pivotal role of HLA molecules in cancer immunology. A deeper understanding of HLA-tumor interactions offers promising avenues for the development of HLA-based immunotherapies, potentially improving clinical outcomes in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.